Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant exemestane or letrozole with or without celecoxib in ER-positive postmenopausal early breast cancer
2006-000436-27Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Dec 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of exemestane, letrozole and celecoxib in breast cancer (4 arms), sponsored by University of Birmingham. Primary endpoint: Objective clinical response during neoadjuvant treatment. Status: unknown.
02
Drugs
exemestaneletrozolecelecoxib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000436-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000436-27.